Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCOPE Trial) -がんと急性低リスク肺塞栓症患者におけるリバーロキサバンの18ヵ月投与と6ヵ月投与の比較：ONCO PE試験-

Journal Club

Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCOPE Trial) -がんと急性低リスク肺塞栓症患者におけるリバーロキサバンの18ヵ月投与と6ヵ月投与の比較：ONCO PE試験-

2025/04/28

Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCOPE Trial)

-がんと急性低リスク肺塞栓症患者におけるリバーロキサバンの18ヵ月投与と6ヵ月投与の比較：ONCO PE試験-

こちら

PageTop